Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05489211
Title	Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	AstraZeneca
Indications	Advanced Solid Tumor
Therapies	Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan + Durvalumab + Saruparib Capecitabine + Datopotamab deruxtecan + Nivolumab Carboplatin + Datopotamab deruxtecan Datopotamab deruxtecan + Fluorouracil Datopotamab deruxtecan + Saruparib Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + Fluorouracil + Nivolumab Bevacizumab + Datopotamab deruxtecan + Fluorouracil + Leucovorin Bevacizumab + Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN